Vascular endothelial growth factor and vascular targeting of solid tumors

Area of Science:

• Oncology
• Vascular Biology
• Immunotherapy

Background:

• Vascular targeting agents selectively destroy tumor vasculature, differing from anti-angiogenic agents by targeting mature vessels.
• These agents are particularly suited for larger tumors where angiogenesis is less prevalent.
• Target molecules on tumor vascular endothelium, such as vascular endothelial growth factor (VEGF) and its receptors (VEGFR), are crucial for therapeutic development.

Purpose of the Study:

• To review the concept of vascular targeting for cancer therapy.
• To discuss the development of monoclonal antibodies targeting VEGF:VEGFR complexes.
• To evaluate the potential of antibody 2C3 as a tumor vascular targeting agent.

Main Methods:

• Review of existing literature on vascular targeting agents and monoclonal antibodies.
• Focus on antibodies that bind to VEGF:VEGFR complexes on tumor vasculature.
• Analysis of antibody 2C3's binding specificity and potential mechanisms of action.

Main Results:

• VEGF production is induced by oncogenic mutations and hypoxia, leading to upregulated VEGFRs on tumor vascular endothelium.
• High concentrations of occupied receptors are found on tumor vascular endothelium.
• Monoclonal antibody 2C3 specifically blocks VEGF binding to VEGFR2, not VEGFR1.

Conclusions:

• Antibody 2C3 demonstrates potential as a dual-action therapeutic agent.
• It may function as an anti-angiogenic agent by inhibiting VEGFR2 activity.
• 2C3 could also serve as a vascular targeting agent for selective drug delivery to tumor vessels.